Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) disclosed a Next Day Disclosure Return on 13 November 2026, detailing the latest execution under its June 2026 share-repurchase mandate.
On 13 November 2026, the company repurchased 1.49 million H-shares on the Hong Kong Stock Exchange at prices ranging from HK$16.41 to HK$16.57, with a volume-weighted average cost of HK$16.55 per share. The aggregate consideration amounted to HK$24.59 million, funded from internal resources.
Following the transaction, Fosun Pharma’s issued share capital (excluding treasury shares) fell by 0.28% to 521.52 million shares, while treasury share holdings rose to 30.42 million. The total issued share count remained unchanged at 551.94 million, as the repurchased shares have been retained in treasury and not yet cancelled.
The 13 November purchase lifts cumulative buybacks under the current mandate—approved at the 16 June 2026 shareholders’ meeting—to 19.45 million shares, equivalent to 3.60% of the company’s issued share base at the time of mandate approval. Fosun Pharma is authorised to repurchase up to 54.10 million shares, leaving roughly 34.64 million shares (about 64% of the mandate) still available for potential future buybacks.
In line with Hong Kong listing rules, Fosun Pharma is subject to a 30-day moratorium on issuing new shares or selling treasury shares until 13 December 2026.
Comments